-
Exelixis Will Not Pursue Untreated Liver Cancer Indication For Cabometyx Combo Therapy
Tuesday, March 15, 2022 - 6:53am | 336Read More...Exelixis Inc (NASDAQ: EXEL) announced results from the final analysis of the second primary endpoint of overall survival (OS) from the phase 3 COSMIC-312 trial of Cabometyx (cabozantinib) plus atezolizumab versus sorafenib in untreated hepatocellular carcinoma (HCC). The final analysis ...
-
Merck's Keytruda Manages To Cross The Finish Line In Liver Cancer Confirmatory Trial
Wednesday, January 19, 2022 - 8:56am | 360Read More...Merck & Co Inc (NYSE: MRK) has posted the final results from the Phase 3 trial of Keytruda (pembrolizumab) plus best supportive care (BSC) in previously treated hepatocellular carcinoma (HCC) patients. Keytruda slashed the risk of death by 21% over placebo in hepatocellular...
-
Merck's Keytruda Tops Placebo On Overall Survival Endpoint In Liver Cancer Patients
Monday, September 27, 2021 - 9:46am | 271Read More...Merck & Co Inc (NYSE: MRK) has announced topline data from Phase 3 KEYNOTE-394 trial of Keytruda in Asian patients with advanced hepatocellular carcinoma (HCC). The trial included HCC patients previously treated with sorafenib. The study met its primary endpoint of overall...
-
Uniqure's Hemophilia B Gene Therapy Unlikely To Be Cause Of Liver Cancer Reported In One Patient
Monday, March 29, 2021 - 9:26am | 464Read More...Uniqure NV (NASDAQ: QURE) has reported results of a comprehensive investigation into the case of hepatocellular carcinoma (HCC) diagnosed in one patient in the HOPE-B pivotal trial of etranacogene dezaparvovec, its hemophilia B gene therapy candidate. What Happened: The...
-
Two New Biotech IPOs Debut Friday, One Deal Delayed
Thursday, January 29, 2015 - 2:47pm | 303Read More...Although Spark Therapeutics Inc (NASDAQ: ONCE) and Shake Shack Inc (NYSE: SHAK) are the most hyped deals of the week, there are two other biotech deals that will debut on Friday, January 30. TRACON Pharmaceuticals Inc (NASDAQ: TCON) is a biotech company focused on developing therapies for cancer,...
